United Therapeutics Stock Price Target and Analyst Ratings (NASDAQ:UTHR)

Analyst Price Target for UTHR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$206.86

▲ +23.03% Upside Potential

This price target is based on 8 analysts offering 12 month price targets for United Therapeutics in the last 3 months. The average price target is $206.86, with a high forecast of $275.00 and a low forecast of $123.00. The average price target represents a 23.03% upside from the last price of $168.14.

Buy

The current consensus among 8 polled investment analysts is to buy stock in United Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
9 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

9/5/2019

0 strong buy ratings
7 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

12/4/2019

0 strong buy ratings
8 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

3/3/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

6/1/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

8/30/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

11/28/2020

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/27/2021

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/26/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/25/2021	Wedbush	Boost Price Target	Outperform	$255.00 ➝ $260.00	Low	i
2/22/2021	Credit Suisse Group	Boost Price Target	Outperform	$169.00 ➝ $196.00	Low	i
2/16/2021	Oppenheimer	Boost Price Target	Outperform	$200.00 ➝ $275.00	Low	i
2/1/2021	HC Wainwright	Upgrade	Neutral ➝ Buy	$125.00 ➝ $195.00	Low	i Rating by A. Fein at HC Wainwright
1/20/2021	Oppenheimer	Boost Price Target	Outperform	$175.00 ➝ $200.00	Low	i
1/20/2021	Cowen	Boost Price Target	Outperform	$160.00 ➝ $200.00	Low	i
1/20/2021	LADENBURG THALM/SH SH	Boost Price Target	Positive ➝ Buy	$151.00 ➝ $199.00	Low	i
10/29/2020	Wedbush	Boost Price Target	Outperform	$247.00 ➝ $255.00	Low	i Rating by Liana Moussatos at Wedbush
10/29/2020	Oppenheimer	Boost Price Target	Outperform	$165.00 ➝ $175.00	Medium	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight		High	i
7/30/2020	Oppenheimer	Boost Price Target	Outperform	$155.00 ➝ $165.00	Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/29/2020	Wedbush	Reiterated Rating	Buy	$243.00 ➝ $244.00	Low	i Rating by Liana Moussatos at Wedbush
6/25/2020	Wedbush	Reiterated Rating	Buy	$243.00	High	i Rating by Liana Moussatos at Wedbush
6/25/2020	Credit Suisse Group	Boost Price Target	Outperform	$129.00 ➝ $145.00	Medium	i
6/25/2020	HC Wainwright	Boost Price Target	Neutral	$85.00 ➝ $125.00	Medium	i
6/24/2020	Oppenheimer	Initiated Coverage	Buy	$155.00	Medium	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/17/2020	Wedbush	Reiterated Rating	Buy	$243.00	High	i Rating by Liana Moussatos at Wedbush
6/12/2020	Cowen	Reiterated Rating	Buy	$145.00	Medium	i Rating by Chris Shibutani at Cowen Inc
4/30/2020	Wedbush	Reiterated Rating	Buy	$243.00	Low	i Rating by Liana Moussatos at Wedbush
4/30/2020	Credit Suisse Group	Reiterated Rating	Buy		Low	i Rating by Martin Auster at Credit Suisse Group AG
3/10/2020	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$115.00 ➝ $123.00	High	i
3/4/2020	Wedbush	Reiterated Rating	Buy	$243.00	Low	i Rating by Liana Moussatos at Wedbush
2/27/2020	Cowen	Upgrade	Market Perform ➝ Outperform	$119.00 ➝ $145.00	High	i Rating by Chris Shibutani at Cowen Inc
2/24/2020	Wedbush	Reiterated Rating	Outperform ➝ Buy	$237.00 ➝ $243.00	High	i Rating by Liana Moussatos at Wedbush
2/13/2020	Credit Suisse Group	Boost Price Target	Outperform	$113.00 ➝ $121.00	Low	i Rating by Martin Auster at Credit Suisse Group AG
2/3/2020	Wedbush	Reiterated Rating	Buy	$237.00	Low	i Rating by Liana Moussatos at Wedbush
1/31/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$116.00 ➝ $120.00	Low	i
1/27/2020	Wedbush	Reiterated Rating	Buy	$237.00	High	i Rating by Liana Moussatos at Wedbush
12/15/2019	Wedbush	Reiterated Rating	Buy	$237.00	Medium	i
12/10/2019	Credit Suisse Group	Reiterated Rating	Buy	$113.00	Low	i Rating by Martin Auster at Credit Suisse Group AG
12/3/2019	Bank of America	Initiated Coverage	Underperform	$80.00	High	i
11/1/2019	HC Wainwright	Reiterated Rating	Hold	$85.00	Low	i
9/13/2019	Cowen	Set Price Target	Hold	$118.00	Low	i Rating by Chris Shibutani at Cowen Inc
8/1/2019	Wedbush	Reiterated Rating	Buy	$273.00	Low	i Rating by Liana Moussatos at Wedbush
8/1/2019	LADENBURG THALM/SH SH	Upgrade	Neutral ➝ Buy	$103.00 ➝ $106.00	High	i Rating by Matthew Kaplan at LADENBURG THALM/SH SH
8/1/2019	Jefferies Financial Group	Upgrade	Underperform ➝ Hold	$90.00	High	i
7/1/2019	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$98.00 ➝ $101.00	High	i
5/17/2019	UBS Group	Upgrade	Sell ➝ Neutral	$115.00 ➝ $94.00	Medium	i
5/9/2019	Credit Suisse Group	Upgrade	Underperform ➝ Neutral	$98.00	Medium	i Rating by Martin Auster at Credit Suisse Group AG
5/8/2019	Wedbush	Set Price Target	Buy	$273.00	Medium	i Rating by Liana Moussatos at Wedbush
5/2/2019	Wedbush	Boost Price Target	Outperform ➝ Outperform	$269.00 ➝ $273.00	High	i Rating by Liana Moussatos at Wedbush
5/1/2019	Cowen	Reiterated Rating	Hold	$103.00	High	i Rating by Chris Shibutani at Cowen Inc
4/9/2019	Oppenheimer	Lower Price Target	Outperform	$160.00 ➝ $155.00	Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/8/2019	Wedbush	Set Price Target	Buy	$269.00	High	i Rating by Liana Moussatos at Wedbush
3/26/2019	Oppenheimer	Set Price Target	Buy	$160.00	Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/26/2019	Credit Suisse Group	Reiterated Rating	Underperform	$105.00 ➝ $98.00	Medium	i Rating by Martin Auster at Credit Suisse Group AG
3/19/2019	Oppenheimer	Reiterated Rating	Buy		Medium	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/1/2019	Barclays	Lower Price Target	Underweight ➝ Underweight	$100.00 ➝ $95.00	Low	i
2/28/2019	LADENBURG THALM/SH SH	Set Price Target	Hold	$124.00	Low	i Rating by Matthew Kaplan at LADENBURG THALM/SH SH
2/27/2019	Cowen	Reiterated Rating	Hold	$109.00	Low	i Rating by Chris Shibutani at Cowen Inc
11/20/2018	Oppenheimer	Set Price Target	Buy	$160.00	Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
11/19/2018	Credit Suisse Group	Boost Price Target	Underperform ➝ Sell	$103.00 ➝ $105.00	Medium	i Rating by Martin Auster at Credit Suisse Group AG
11/15/2018	Cowen	Set Price Target	Hold	$106.00	High	i Rating by Chris Shibutani at Cowen Inc
11/2/2018	JPMorgan Chase & Co.	Boost Price Target	Neutral ➝ Neutral	$118.00 ➝ $126.00	Low	i
11/1/2018	Credit Suisse Group	Lower Price Target	Underperform ➝ Underperform	$106.00 ➝ $103.00	Low	i
11/1/2018	HC Wainwright	Reiterated Rating	Hold	$95.00	High	i Rating by Andrew Fein at HC Wainwright
10/31/2018	Cowen	Set Price Target	Hold	$106.00	High	i Rating by Chris Shibutani at Cowen Inc
10/12/2018	Standpoint Research	Upgrade	Hold ➝ Buy		Low	i
9/27/2018	Wedbush	Set Price Target	Buy	$253.00	High	i Rating by Liana Moussatos at Wedbush
9/4/2018	Wedbush	Set Price Target	Buy	$253.00	High	i Rating by Liana Moussatos at Wedbush
8/13/2018	HC Wainwright	Set Price Target	Hold	$95.00	Medium	i Rating by Andrew Fein at HC Wainwright
8/8/2018	Wedbush	Set Price Target	Buy	$253.00	Low	i Rating by Liana Moussatos at Wedbush
8/8/2018	Credit Suisse Group	Downgrade	Neutral ➝ Underperform		Low	i
8/2/2018	Cowen	Reiterated Rating	Hold	$110.00	Medium	i
8/2/2018	Barclays	Reiterated Rating	Sell	$100.00	High	i
8/2/2018	HC Wainwright	Reiterated Rating	Hold	$95.00	High	i
8/2/2018	Wedbush	Boost Price Target	Outperform ➝ Outperform	$234.00 ➝ $253.00	High	i
7/10/2018	Credit Suisse Group	Boost Price Target	Neutral ➝ Neutral	$104.00 ➝ $107.00	Medium	i
5/3/2018	Barclays	Lower Price Target	Underweight ➝ Underweight	$105.00 ➝ $95.00	Medium	i
5/3/2018	Credit Suisse Group	Lower Price Target	Neutral ➝ Neutral	$108.00 ➝ $104.00	Medium	i
4/3/2018	Credit Suisse Group	Upgrade	Underperform ➝ Neutral	$115.00	High	i
2/22/2018	Barclays	Reiterated Rating	Underweight ➝ Underweight	$115.00 ➝ $105.00	Low	i
2/22/2018	Credit Suisse Group	Reiterated Rating	Underperform ➝ Underperform	$120.00 ➝ $115.00	Medium	i
1/18/2018	Credit Suisse Group	Reiterated Rating	Underperform ➝ Underperform	$118.00	Low	i
1/5/2018	Oppenheimer	Boost Price Target	Outperform	$180.00	Low	i
12/27/2017	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$213.00 ➝ $232.00	Medium	i
10/27/2017	Cowen	Reiterated Rating	Hold	$129.00	N/A	i
10/26/2017	HC Wainwright	Reiterated Rating	Hold	$95.00	N/A	i
9/8/2017	Oppenheimer	Reiterated Rating	Buy		Low	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/14/2017	Jefferies Financial Group	Reiterated Rating	Sell	$105.00	Low	i
7/6/2017	UBS Group	Reiterated Rating	Sell	$106.00	Low	i
6/8/2017	Jefferies Financial Group	Reiterated Rating	Sell	$105.00	Low	i
4/28/2017	Jefferies Financial Group	Reiterated Rating	Underperform	$116.00 ➝ $105.00	Low	i
4/27/2017	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$229.00 ➝ $213.00	Low	i
4/26/2017	Cowen	Reiterated Rating	Hold	$121.00	Low	i
4/17/2017	HC Wainwright	Reiterated Rating	Hold	$95.00	Low	i
4/12/2017	Jefferies Financial Group	Reiterated Rating	Sell	$116.00	Low	i
4/11/2017	JPMorgan Chase & Co.	Set Price Target	Hold	$125.00	Low	i Rating by Jessica Fye at JPMorgan Chase & Co.
4/4/2017	Wedbush	Reiterated Rating	Outperform	$229.00	Low	i
4/3/2017	Cowen	Downgrade	Outperform ➝ Market Perform	$140.00 ➝ $121.00	Low	i Rating by Chris Shibutani at Cowen Inc
4/3/2017	Oppenheimer	Reiterated Rating	Buy		Medium	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/3/2017	Credit Suisse Group	Reiterated Rating	Underperform	$120.00	High	i
3/29/2017	UBS Group	Initiated Coverage	Sell ➝ Sell	$112.00	N/A	i
3/17/2017	Jefferies Financial Group	Reiterated Rating	Underperform	$116.00	High	i
3/16/2017	Credit Suisse Group	Initiated Coverage	Underperform ➝ Underperform	$120.00	High	i
3/6/2017	Jefferies Financial Group	Downgrade	Hold ➝ Underperform	$149.47 ➝ $116.00	N/A	i
2/27/2017	Wedbush	Reiterated Rating	Outperform	$229.00	N/A	i
2/23/2017	LADENBURG THALM/SH SH	Downgrade	Buy ➝ Neutral	$145.00	N/A	i
2/23/2017	SVB Leerink	Boost Price Target	Market Perform	$127.00 ➝ $148.00	N/A	i
2/22/2017	Oppenheimer	Set Price Target	Buy	$160.00 ➝ $175.00	N/A	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/14/2017	Oppenheimer	Reiterated Rating	Buy		N/A	i Rating by Hartaj Singh at Oppenheimer Holdings Inc.
2/8/2017	Wedbush	Reiterated Rating	Outperform	$229.00	N/A	i
1/27/2017	Wedbush	Reiterated Rating	Outperform	$229.00	N/A	i
1/19/2017	Standpoint Research	Downgrade	Buy ➝ Hold		N/A	i
1/5/2017	Wedbush	Reiterated Rating	Outperform	$229.00	N/A	i
12/14/2016	Oppenheimer	Initiated Coverage	Outperform	$160.00	N/A	i
11/29/2016	Barclays	Downgrade	Equal Weight ➝ Underweight	$115.00 ➝ $100.00	N/A	i
11/4/2016	Wedbush	Reiterated Rating	Outperform	$229.00	N/A	i
10/28/2016	LADENBURG THALM/SH SH	Upgrade	Neutral ➝ Buy	$128.00 ➝ $138.00	N/A	i
10/27/2016	Cowen	Set Price Target	Buy	$144.00	N/A	i Rating by Chris Shibutani at Cowen Inc
9/23/2016	Cowen	Reiterated Rating	Buy	$144.00	N/A	i Rating by Phil Nadeau at Cowen Inc
8/23/2016	Argus	Reiterated Rating	Hold		N/A	i
7/29/2016	JPMorgan Chase & Co.	Lower Price Target	Neutral	$145.00 ➝ $129.00	N/A	i
7/29/2016	Jefferies Financial Group	Reiterated Rating	Hold	$120.00	N/A	i
7/29/2016	HC Wainwright	Reiterated Rating	Hold		N/A	i Rating by Andrew Fein at HC Wainwright
7/28/2016	Wedbush	Reiterated Rating	Outperform	$229.00	N/A	i Rating by Liana Moussatos at Wedbush
6/15/2016	HC Wainwright	Downgrade	Buy ➝ Neutral	$175.00 ➝ $95.00	N/A	i Rating by Andrew Fein at HC Wainwright
5/24/2016	Argus	Downgrade	Buy ➝ Hold	$114.00	N/A	i
5/7/2016	Cowen	Reiterated Rating	Outperform	$139.00	N/A	i Rating by Phil Nadeau at Cowen Inc
4/29/2016	LADENBURG THALM/SH SH	Downgrade	Buy ➝ Neutral		N/A	i
4/28/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Phil Nadeau at Cowen Inc
4/25/2016	Wedbush	Reiterated Rating	Outperform	$229.00	N/A	i Rating by Liana Moussatos at Wedbush
4/17/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Phil Nadeau at Cowen Inc
4/16/2016	SVB Leerink	Reiterated Rating	Market Perform		N/A	i
4/11/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$150.00 ➝ $122.00	N/A	i
3/24/2016	Wedbush	Reiterated Rating	Outperform	$238.00 ➝ $229.00	N/A	i Rating by Liana Moussatos at Wedbush
3/2/2016	Wedbush	Lower Price Target	Outperform	$244.00 ➝ $238.00	N/A	i Rating by Liana Moussatos at Wedbush
2/28/2016	HC Wainwright	Reiterated Rating	Buy	$175.00	N/A	i Rating by Andrew Fein at HC Wainwright
2/26/2016	Royal Bank of Canada	Lower Price Target	Sector Perform	$175.00 ➝ $150.00	N/A	i
2/26/2016	SVB Leerink	Lower Price Target	Market Perform	$166.00 ➝ $125.00	N/A	i
2/26/2016	Barclays	Lower Price Target	Equal Weight	$155.00 ➝ $145.00	N/A	i

(Data available from 2/26/2016 forward)

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $168.14

$165.98

$170.08

50 Day Range

MA: $168.56

$155.79

$174.85

52 Week Range

Now: $168.14

$75.58

$181.14

Volume

4,430 shs

Average Volume

326,887 shs

Market Capitalization

$7.47 billion

P/E Ratio

15.91

Dividend Yield

N/A

Beta

0.52

Frequently Asked Questions

What sell-side analysts currently cover shares of United Therapeutics?

The following sell-side analysts have issued research reports on United Therapeutics in the last twelve months: Cowen Inc, Credit Suisse Group AG, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., LADENBURG THALM/SH SH, Oppenheimer Holdings Inc., TheStreet, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for UTHR.

What is the current price target for United Therapeutics?

7 Wall Street analysts have set twelve-month price targets for United Therapeutics in the last year. Their average twelve-month price target is $206.86, suggesting a possible upside of 22.8%. Oppenheimer Holdings Inc. has the highest price target set, predicting UTHR will reach $275.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $123.00 for United Therapeutics in the next year.
View the latest price targets for UTHR.

What is the current consensus analyst rating for United Therapeutics?

United Therapeutics currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe UTHR will outperform the market and that investors should add to their positions of United Therapeutics.
View the latest ratings for UTHR.

What other companies compete with United Therapeutics?

Other companies that are similar to United Therapeutics include Amgen, Gilead Sciences, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Biogen, Alexion Pharmaceuticals, Seagen, Exact Sciences, Incyte, Alnylam Pharmaceuticals, BioMarin Pharmaceutical, Novavax, Repligen, Neurocrine Biosciences and Ionis Pharmaceuticals.

How do I contact United Therapeutics' investor relations team?

United Therapeutics' physical mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company's listed phone number is 301-608-9292 and its investor relations email address is [email protected] The official website for United Therapeutics is www.unither.com.

NASDAQ:UTHR - United Therapeutics Stock Price Target and Predictions

Analyst Price Target for UTHR

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of United Therapeutics?

What is the current price target for United Therapeutics?

What is the current consensus analyst rating for United Therapeutics?

What other companies compete with United Therapeutics?

How do I contact United Therapeutics' investor relations team?